CDKN1A and familial pancreatic carcinoma: The observed inhibitory effects of pristimerin on cyclin D1, cyclin E, cdk2, cdk4 and cdk6, along with its upregulating effects on WAF1/p21 and KIP1/p27 in pancreatic cancer cells suggest its potential in disruption of the uncontrolled cell cycle progression.